Medable Inc., a leader in clinical trial technology, has introduced Medable Studio, an advanced platform designed to simplify the configuration, translation, validation, and deployment of eCOA solutions, including eCOA, eConsent, Televisit, and Sensors. This no-code solution offers biopharmaceutical companies enhanced control and transparency, accelerating study initiation and patient recruitment.
Revolutionising Study Setup
Medable Studio dramatically reduces the time needed to develop protocol-compliant studies, which traditionally required months, to mere hours. Its intuitive design allows users, regardless of technical expertise, to build and launch complex clinical trials efficiently. By integrating with Medable’s cloud-based platform, sponsors benefit from continuous updates and access to cutting-edge features. This shift from a services-based model to a technology-driven approach brings greater clarity, control, and speed to the process.
Key Features of Medable Studio
- User-Friendly Builder: Quickly design and configure assessments, instruments, and diaries using a no-code interface, with features including live previews, branching rules, and multilingual support.
- Visual Schedule Builder: Seamlessly add and organize assessments and instruments within study schedules, and configure standard, unscheduled, and remote visits.
- Efficient Translation Management: Simplify translation workflows with a dedicated workbench that allows for easy editing and importing, reducing delays and resource consumption.
- Centralised Content Library: Manage and store assessments, instruments, translations, and locales in one place for convenient reuse across different studies.
Transforming Trial Efficiency
Tim Smith, Chief Technology Officer and co-founder of Medable, praised the platform’s impact: “Medable Studio transforms the traditional study development process through intelligence and automation. What previously took weeks or months is now achievable in days. Our clients have noted significant improvements in speed, scale, and quality, providing them with comprehensive control and insight.”
Driving Innovation in Clinical Trials
Michelle Longmire, CEO and co-founder of Medable, highlighted the platform’s role in advancing clinical trials: “Medable Studio marks a pivotal shift in how evidence is generated. It offers unmatched scalability and efficiency, setting new standards for trial execution. Our goal is to expedite the availability of effective treatments by reducing trial start-up times and costs.”
Proven Success
Medable Studio is now available as part of Medable’s comprehensive software-as-a-service platform, which includes eCOA+, Total Consent, Sensors, and Televisit. Medable, ranked among the top 8% of software companies in the 2023 Inc. 5000, has implemented its platform in over 300 decentralized and hybrid clinical trials across 60 countries. The platform has supported more than one million patients and research participants, achieving results such as 200 percent faster enrollment and 50 percent cost savings. According to a Tufts CSDD study, decentralized trials can provide substantial financial returns, with net benefits ranging from five to thirteen times the investment, averaging $10 million for Phase II and $39 million for Phase III trials.
